Literature DB >> 3058752

A clinical trial to assess the efficacy of sanguinarine-zinc mouthrinse (Veadent) compared with chlorhexidine mouthrinse (Corsodyl).

J Moran1, M Addy, R Newcombe.   

Abstract

A single-blind crossover study was used to compare the ability of a 0.2% chlorhexidine mouthrinse (Corsodyl) with a sanguinarine-zinc mouthrinse (Veadent) to inhibit plaque and gingivitis. 14 volunteers starting with plaque-free mouths and optimal gingival health, rinsed with the preparations over two 19-day periods whilst refraining from all other oral hygiene procedures. At days 8, 15 and 19 of the trial, Corsodyl was significantly more effective at inhibiting both plaque and gingivitis. The findings of this study would suggest that the Veadent mouthrinse would at most only have a limited rôle as an inhibitor of plaque and gingivitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3058752     DOI: 10.1111/j.1600-051x.1988.tb02260.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  3 in total

Review 1.  Natural compounds containing mouthrinses in the management of dental plaque and gingivitis: a systematic review.

Authors:  Yong Chen; Ricky W K Wong; Colman McGrath; Urban Hagg; C Jayampath Seneviratne
Journal:  Clin Oral Investig       Date:  2013-07-17       Impact factor: 3.573

2.  Comparison of laser therapy and ozonated water on gingival inflammation in orthodontic patients with fixed appliances.

Authors:  V Kala Vani Sandra; Ziauddhin Shaik; Geetika Simhadri; Lakshmikar Reddy Obili Govindu Gari; Bindu Priya Siddamreddy; Naveen Makem
Journal:  J Clin Transl Res       Date:  2021-09-27

3.  Maximum inhibitory dilution of mouthwashes containing chlorhexidine and polyhexamethylene biguanide against salivary Staphylococcus aureus.

Authors:  Andresa Piacezzi Nascimento; Juliane Maria Guerreiro Tanomaru; Fumio Matoba-Júnior; Evandro Watanabe; Mario Tanomaru-Filho; Izabel Yoko Ito
Journal:  J Appl Oral Sci       Date:  2008 Sep-Oct       Impact factor: 2.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.